Stock Ratings / Health Care / SPTX / options

MNKD (63) HROW (71) AVLN (49) CTY (61) ⌘ Pro Terminal →

Seaport Therapeutics Inc. (SPTX) Options Positioning, Max Pain & Unusual Sweeps

$21.10 +3.53% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $21.19

Seaport Therapeutics Inc. (SPTX) carries a Roarable Rating of D+ (Sell) with 56/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 56/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.4% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $1.13B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $21.19 (+0.45%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 0.8% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 56/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.4% avg 90D alpha vs SPY • 51.8% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-0.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SPTX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (56/100 Composite)

🔍 WHY SPTX SCORES 56/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (23% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Macro Regime Fit+13/20 pts (23% of score)

FRED Regime × Technicals: 46% of 52W Range • RSI-14 at 48.7 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$18.15-1.8% Next Q

Q2 (-2Q)

Grade C-$17.83+15.6% Next Q

Q3 (-1Q)

Grade C-$20.61+2.4% Next Q

Current

Grade D+$21.10-0.4% Hist 90D α

Trajectory: D (48) → D+ (56)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the SPTX Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 56/100 (D+) score, SPTX faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($21.16) or 200D SMA ($20.13) invalidates the momentum regime and cuts Target Base ($20.91) toward Bear Floor ($16.31).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SPTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SPTX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 56%NO 44%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (SPTX)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for SPTX.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SPTX)

✓Walkthrough of SPTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SPTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +6.35%📐 HORIZONTAL RANGE

2026-10-30O $20.96H $21.16L $19.00C $21.10VOL 549.2K

RES: $34.31SUP: $15.03SMA50: $21.16SMA200: $20.13

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SPTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SPTX Butterfly Map → + Track SPTX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SPTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SPTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SPTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SPTX)

Health Care Rank #265 of 1016 ⚔️ MNKD vs SPTX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SPTX vs. MNKD, HROW, AVLN, CTY)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Seaport Therapeutics Inc. (SPTX) ranks #265 by composite RQD confidence (56/100, grade D+) and #346 by equity capitalization ($1.13B). Within this direct 5-issuer industry benchmark cohort, SPTX leads on earnings valuation at N/A trailing P/E, while MNKD leads on capital efficiency and profitability with 54.5% ROIC and 92.3% gross margin. HROW currently holds the highest overall quantitative score in the immediate peer group at 71/100 (B-) compared with SPTX at 56/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SPTX ACTIVE Seaport Therapeutics Inc.	D+	56/100	—	—	—	+3.53%	$1.13B	Benchmark Subject
MNKD MannKind Corporation	C	63/100	—	92.3%	54.5%	+2.04%	$1.13B	/mnkd-vs-sptx →
HROW Harrow Inc.	B-	71/100	—	75.1%	42.9%	+2.04%	$1.12B	/hrow-vs-sptx →
AVLN Avalyn Pharma Inc.	D	49/100	—	—	—	-0.12%	$1.14B	/avln-vs-sptx →
CTY City Therapeutics Inc.	C-	61/100	—	—	—	+2.26%	$1.11B	/cty-vs-sptx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002042347

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Seaport Therapeutics Inc. (SPTX) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, SPTX closed FY2025 with $249.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$0	—	—	$249.0M	—

3. SPTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SPTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Seaport Therapeutics Inc. (NASDAQ: SPTX) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 56/100 at a spot price of $21.10 (+3.53% 1D, market cap $1.13B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, SPTX ranks #265 in composite RQD confidence.

How does SPTX compare to MNKD and HROW in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SPTX carries a Roarable D+ (56/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, MNKD (MannKind Corporation) holds a C grade (63/100 RQD, P/E N/A, ROIC 54.5%, cap $1.13B) and HROW (Harrow Inc.) posts a B- grade (71/100 RQD, P/E N/A, ROIC 42.9%, cap $1.12B). Among the 5-stock peer group, SPTX leads on earnings multiple (N/A) while MNKD leads on capital efficiency (54.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SPTX?

Per SPTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002042347), Seaport Therapeutics Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $249.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SPTX trading relative to its 50-day, 200-day, and 52-week technical levels?

SPTX last traded at $21.10 (+3.53% on volume of 272,154 shares), positioning the stock -0.28% below its 50-day simple moving average ($21.16) and +4.82% above its 200-day simple moving average ($20.13). Across its 52-week range of $14.85 to $28.38, SPTX sits at the 46.2% percentile with a 14-day RSI of 48.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($18.46 to $23.74).

SPTX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is SPTX's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for SPTX.

Direct Sub-Reports: SPTX RQD Cockpit SPTX 12M Forecast SPTX Earnings & Move SPTX Dividends & DRIP SPTX Insiders & 13F SPTX Whale Options SPTX Profit Sankey SPTX News & Why